All News
The Need for Comparative Treatment Trials in Psoriatic Arthritis
Psoriatic arthritis is currently experiencing a burgeoning selection of treatment options. While this is a very welcome development in a disease which has had less treatment options compared to RA, it leaves us with a difficult conundrum: which agent to choose for an individual patient.
Read Article
RheumNow’s expanded coverage of the #ACR21 Annual meeting is sponsored in part by @Novartis. All content chosen by RheumNow & its Faculty.
Dr. John Cush RheumNow ( View Tweet)
Predicting RA, and Treatment of Subclinical Arthritis
Dr. Meral K. El Ramahi ( @MeralElRamahiMD) shares the abstracts discussed at #ACR21 focusing on predicting RA and treating subclinical arthritis.
https://t.co/DYgV43JpgT https://t.co/U2NfXrfYZU
Links:
Dr. John Cush RheumNow ( View Tweet)
My article on the potential use of BMI to guide biologic selection in RA. Discussing #ACR21 abstract 0588 by @MilenaGianfran @JYazdanyMD https://t.co/hxliSZ3IBS @RheumNow
Richard Conway RichardPAConway ( View Tweet)
Watch back our recap of the best from Day 2 of #ACR21 in the @RheumNow daily panel. With @AurelieRheumo @RheumNow @Yuz6Yusof @bella_mehta @_Castillo_Pedro https://t.co/ORTbV61c2C
Richard Conway RichardPAConway ( View Tweet)
Watch my video of #ACR21 Abstract 1456, a double blind RCT of CBD for hand OA and PsA @RheumNow https://t.co/p0IiYzYe2m
Richard Conway RichardPAConway ( View Tweet)
Watch my video discussion of #ACR21 abstract 564 from @KronzerMD @jeffsparks on the association of upper airways disease with incident RA. https://t.co/Nkg9Yl9yYT @RheumNow
Richard Conway RichardPAConway ( View Tweet)
This case is from the hypereosinophilic syndrome talk. This was NOT EGPA! It was cancer. Be careful! #ACR21 @RheumNow https://t.co/UhdpeHBfOE
Richard Conway RichardPAConway ( View Tweet)
What is the effect of long-term #steroid use on major adverse #cardiovascular events (MACE)?
Find out in my video summary of abstract #1428 which was presented yesterday by @BethIWallace
Read here👉🏼https://t.co/fCM3m04ruS
Watch here👉🏼https://t.co/TLerQT7XnG
#ACR21 @RheumNow
Links:
Mrinalini Dey DrMiniDey ( View Tweet)
Avoid IFX drug holidays!
In this study 400+ pts
Dvlpmt of ADAs associated w/
▶️RA vs. SPA OR 2.1
▶️Smoking OR 1.8
▶️Drug holidays > 11 weeks OR 4.1
▶️High DA OR 1.5
while
◀️Concomitant IS drug OR 0.4
◀️ IFX dose increments OR 0.4, were protective #ACR21 @RheumNow #Abst1525 https://t.co/cxx7aWX5wh
Aurelie Najm AurelieRheumo ( View Tweet)
My video comment on the cannabidiol (CBD) double-blinded RCT in hand OA/inactive PsA #ACR21 for @RheumNow
Great work by @Joner_MD et al
& kudos to funders @PsoriasisDK @Gigtforeningen @AalborgUH @aalborguni giving us data to answer a question often asked
https://t.co/e0mO0SriUu https://t.co/9DveN4jLls
Links:
David Liew drdavidliew ( View Tweet)
#ACR21 #Abstr1541 Any tools to help differentiate MAS vs #COVID inflammatory response? Preliminary criteria showed Sensitivity: 79.6%; Specificity: 81.3% within 6 days admission. No Triglyceride/Fibrinogen compared to 2016 ACR-EULAR & 2004 HLH @RheumNow https://t.co/c7pHaVCr5S https://t.co/6irF64qizI
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#ACR21 #Abstr1876 The fact that nothing is 100% makes Medicine interesting! If you have patients who meet McAdams/Damiani criteria for relapsing polychondritis OR ICBD for Behcet, don’t forget it could be MAGIC! Anticollagen II abs may help @RheumNow https://t.co/9ZjYbWC6Td https://t.co/xbh9ahp2fh
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Guselkumab 100 mg Q4W and Q8W provided robust and sustained benefits to patients with active PsA across multiple domains. Listen to my interview with Prof. Laura Coates on this and other emerging treatments in PsA here https://t.co/PSbJ0HA5a6
@RheumNow #ACR21 Abstr#1335 https://t.co/WzBOYGOxAA
Dr. Antoni Chan synovialjoints ( View Tweet)
Will a FDA black box warning change your JAKi practice?
In May 2019, the EMA put out a warning about VTE with tofacitinib.
In this French cohort, did it change the kind of pts they initiated on JAKi?
no, not it did not😊
A window into the US future?
#ACR21 ABST1245 @RheumNow https://t.co/QI95E1gepg
David Liew drdavidliew ( View Tweet)
Are there people looking at steroid-sparing therapy as irAE treatment or prevention?
@CCalabreseDO: are there ever
#ACR21 irAE Study Group @RheumNow
(also @NAbdelwahabMD @ReidMDMPH on stage) https://t.co/CLmNaLB68O
David Liew drdavidliew ( View Tweet)
#ACR21 Abs#1536
#Vaccine uptake in people with #RheumaticDisease
👉🏼High uptake of vaccines in ~240 pts @BrighamWomens
👉🏼84% pts wanted the #COVID19 vaccine
👉🏼Physician recommendation was key determinant of uptake
@RheumNow
https://t.co/us0i5CW5Mi https://t.co/aLZmOPWFR3
Mrinalini Dey DrMiniDey ( View Tweet)
#ACR21 #Abstr1492 Could gut microbiome contribute to Anti-Ro+/autoimmunity in #lupus? Analyses of 125 stool samples from mother of children with neonatal lupus and/or heart block revealed its potential role in genetic-environment interaction @RheumNow https://t.co/FnJtZJSCRj https://t.co/ttRdP9NIrG
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Safety profile of #upadacitinib in #RA, #PsA, #AnkylosingSpondylitis
👉🏼AE rates similar across UPA, ADA & MTX in RA, and UPA & ADA in PsA
👉🏼No new safety risks with long-term use
👉🏼#Herpeszoster & incr CPK more common w/ UPA vs ADA/MTX
Abs#1691 #ACR21 @RheumNow https://t.co/tKYi65kB5r
Mrinalini Dey DrMiniDey ( View Tweet)
#ACR21 Abs#1677. Effects of bDMARD on Lipids:
⬆️ HDL from 62 -> 66 in 1yr (p=0.013)
❌ No signif change in LDL or LDL-C/HDL-C ratios
@Rheumnow
https://t.co/uMsXKwwqvW https://t.co/fhCbDoa3px
Links:
Eric Dein ericdeinmd ( View Tweet)